Category Archives: Biochemistry

The Global Automated Biochemistry Analyzers Market Status and Trend Analysis 2017-2026 (COVID-19 Version) 2020-2026 report is one of the most comprehensive and important data about business strategies, qualitative and quantitative analysis of Global Market. Automated Biochemistry Analyzers Market research report offers extensive research and analysis of key aspects of the global Automated Biochemistry Analyzers market. The report provides deeper understanding of the competitive landscape and its future scenarios, crucial dynamics, and leading segments of the global Automated Biochemistry Analyzers market. The report also provides accurate PESTLE, SWOT and other types of analysis on the global Automated Biochemistry Analyzers market. The market study has examined the competitive trend apart from offering valuable insights to clients as well as industries. This report concentrate on the global Automated Biochemistry Analyzers status, future forecast, development opportunity, key market and key players.

Major companies listed in the market includes:

AbbottDanaherHitachiRocheSiemensThermo Fisher Scientific

Request for a Sample Report of Automated Biochemistry Analyzers Market: https://www.apexmarketreports.com/Heavy-Industry/global-automated-biochemistry-analyzers-market-by-product-type-635778#inquiry

The report on Global Automated Biochemistry Analyzers Market 2020 cover big geographical, as well as, sub-regions throughout the world. The study objectives of the report are to present the Automated Biochemistry Analyzers development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America. The aim of the report is to get premium insights, quality data figures and information in relation to aspects such as market scope, market size, share, and segments such as Types of Products and Services, Application/end use industry, SWOT Analysis and by different emerging by geographies.

Covid-19 Impact Update Global Automated Biochemistry Analyzers Market Research

The report also provides how this industry is likely to be impacted as a result of the global COVID-19 pandemic: market size by revenue is expected to grow xx% in 2020 alone as demand is anticipated to be moderately affected by the outbreak of COVID-19. The downstream companies contend with restricted profit from falling consumer confidence, demand for industry products is expected to slow. Demand from top notch companies and government agencies is expected to rise as they seek more information on COVID-19.

Apart from that, the report also provides valuable differentiating information regarding each of the market segments. These segments are examined further on different fronts such as historical performance, market size contributions, % market share, expected rate of growth.

Request Sample Enquiry Buying

Key Businesses Segmentation or Breakdown covered in Automated Biochemistry Analyzers Market Study

On the Basis of Type

Stationary Biochemistry AnalyzersPortable Biochemistry Analyzers

On the Basis of Application

Hospital and Diagnostic LaboratoriesHome Care, and AcademicResearch Institutes

On the Basis of Region

The report is mainly segmented into several key regions, with sales, revenue, market share and growth rate of Automated Biochemistry Analyzers in these regions, from 2020 to 2027, covering:

Enquire Here for, Report Enquire, Discount and Customization: https://www.apexmarketreports.com/Heavy-Industry/global-automated-biochemistry-analyzers-market-by-product-type-635778#inquiry

The Automated Biochemistry Analyzers Market Key Offering:

Business Strategies

Key strategies in the global Automated Biochemistry Analyzers market like product developments, partnerships, mergers and acquisitions, etc., analysed in this report. The worth of strategic analysis has been rigorously investigated in conjunction with undisputed market challenges. The Automated Biochemistry Analyzers market report delivers conclusion that includes breakdown and data triangulation, consumer needs/customer preference change, research findings, market size estimation, data source. These factors will increase the business overall.

About Us:

We at Apex Market Reports aim to be global leaders in qualitative and predictive analysis as we put ourselves in the front seat for identifying worldwide industrial trends and opportunities and mapping them out for you on a silver platter. We specialize in identifying the calibers of the markets robust activities and constantly pushing out the areas which allow our clientele base in making the most innovative, optimized, integrated and strategic business decisions in order to put them ahead of their competition by leaps and bounds. Our researchers achieve this mammoth of a task by conducting sound research through many data points scattered through carefully placed equatorial regions.

Contact Us:

Apex Market Reports1st Floor, Harikrishna Building,Samarth Nagar, New Sanghvi,Pune- 411027 Indiatel: +91-8149441100 (GMT Office Hours)tel: +17738002974sales@apexmarketsreports.com

Go here to read the rest:
Automated Biochemistry Analyzers Market by Manufacturers, Regions, Type and Application, Forecast To 2026 Abbott, Danaher, Hitachi, Roche, Siemens -...

A recent market study published by MarketandResearch.biz with the title Global Biochemistry Analyzing Systems Market Growth 2020-2025 is an expert and top to bottom investigation of the market condition with an attention on the market. The report conducts thorough research on the historical, as well as current growth parameters of the market, the growth prospects of the market, are obtained with maximum precision. The report covers key insights available status of the producers and is an important source of direction and course for organizations and people keen on the business. By and large, the report gives an inside and out understanding of the 2020-2025 worldwide market covering extremely significant parameters. The market is segmented in detail to cover every aspect of the market and present complete market intelligence to readers.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Executive Summary:

The market report highlights the growth driving factors, opportunities, and challenges that will impact the industry growth in the ensuing years. The report presents an in-depth analysis of key business trends and future market development prospects, key drivers and limitations, the profile of key market players, segmentation, and forecasts. It provides an extensive view of size, trends, demand-side and supply-side trends, and opportunity assessment. The study offers a detailed examination of various market segments to deliver a clear understanding of the revenue prospects of this global Biochemistry Analyzing Systems industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketandresearch.biz/sample-request/150398

Our exploration specialists acutely discover the significant aspects of the global market report. It also provides an in-depth valuation in regards to the future advancements relying on the past data and present circumstances of the global Biochemistry Analyzing Systems market situation. In this report, we have investigated the principals, players in the market, geological regions, product type, and market end-client applications. With this market report, businesses can acquire details about market drivers and market restraints which assist them to take presumption about reducing or increasing the production of a particular product.

Key players profiled in the report include: Roche, Mindray Medical, Siemens Healthcare, Horiba Medical, EKF Diagnostics, Abbott, Balio Diagnostics, Randox Laboratories, Hitachi, Nihon Kohden Europe, Tianjin MNCHIP Technologies Co., Ltd,

On the basis of product type, the market study incorporates: Full Automatic Systems, Semi-Automatic Systems,

On the basis of application, the market study incorporates: Clinical Diagnostic, Drug Testing, Other

The countries covered in the market report are: Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

Moreover, the report examines all the key factors influencing the growth of the global Biochemistry Analyzing Systems market, including the demand-supply scenario, pricing structure, profit margins, production, and value chain analysis. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, pricing strategies, innovation possibilities, and much more.

ACCESS FULL REPORT: https://www.marketandresearch.biz/report/150398/global-biochemistry-analyzing-systems-market-growth-2020-2025

Why The Market Report Is Beneficial?

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketandresearch.bizWeb: http://www.marketandresearch.biz

Read more:
Global Biochemistry Analyzing Systems Market 2020 Technological Strategies, Business Advancements and Top-Vendor Landscape by 2025 - BAVIATION...

When Terrie Williams began hearing about the wide range of symptoms experienced by patients with COVID-19, she saw a connection between the various ways the disease is affecting people and the many physiological adaptations that have enabled marine mammals to tolerate low oxygen levels during dives.

Williams, a professor of ecology and evolutionary biology at UC Santa Cruz, has spent decades studying the physiology of marine mammals and their extraordinary ability to perform strenuous activities while holding their breath for long periods under water.

Diving marine mammals experience a lifetime of rapid physiological transitions between normal oxygenation and hypoxia [low oxygen levels], Williams said. Theyve got ways to protect themselves and allow their organs to keep functioning while holding their breath for hours at a time, but theres a whole suite of biological adaptations that had to happen for them to be able to do that.

Lacking those adaptations, humans are vulnerable to rapid damage in a wide range of tissues when oxygen levels drop due to the effects on the lungs and cardiovascular system of infection with the coronavirus SARS-CoV-2. In a review articlepublished December 3 inComparative Biochemistry and Physiology, Williams explores how the diving physiology of marine mammals can help us understand the effects of COVID-19.

It really highlights why it is so important for people to protect themselves from infection with this virus, she said. Damage to oxygen-deprived tissues happens fast and can be irreversible, which may account for the long-term effects we are beginning to see in people after coronavirus infections.

The heart and brain are especially sensitive to oxygen deprivation, and marine mammals have multiple mechanisms to protect these and other critical organs. In the first place, marine mammals have much higher oxygen carrying capacity than humans due to their greater blood volume and hemoglobin concentrations. In addition, some marine mammals contract their spleen during dives to release a store of oxygen-rich blood cells into the circulation. To avoid blood clots resulting from such high concentrations of red blood cells, many species lack a key clotting factor found in other mammals.

Other adaptations include greatly increased concentrations of oxygen-carrying proteins such as myoglobin in heart and skeletal muscles and neuroglobin and cytoglobin in the brain. In addition, numerous safety factors and biochemical buffers enable even the most oxygen-dependent tissues in marine mammals to withstand not only low oxygen but also the subsequent reperfusion of tissues with oxygenated blood. In humans, reperfusion after a heart attack or stroke often leads to additional tissue damage.

According to Williams, the solutions that marine mammals have evolved for tolerating hypoxia provide a natural template for understanding the potential for damage to oxygen-deprived tissues in humans.

Studying marine mammals allowed me to understand what it takes to protect the body when the availability of oxygen is low, she said. There are so many ramifications of shutting down the oxygen pathway, and I think thats what were seeing in these COVID patients.

Williams is particularly concerned about the so-called long-haulers who continue to have symptoms long after they were infected with the coronavirus.

You hear people say its just like the flu, but COVID scares the heck out of me because of the potential for long-term damage to the heart and brain, she said. When you think about oxygen deprivation and the tissue repair process, it makes sense that many people are having a hard time getting back to normal life, even after a mild infection.

Williams urges people to do all they can to avoid becoming infected. Our heart and brain cells are meant to last a lifetime, and we cannot replace them once they are damaged, she said. Dolphins and whales have natural protections that humans lack, so we are highly vulnerable to hypoxia.

Randall Davis, a marine biologist at Texas A&M University, coauthored the paper with Williams. This work was funded by the Office of Naval Research.

Visit link:
What dolphins can teach us about surviving COVID-19 - University of California

This article was originally published here

Adv Radiat Oncol. 2020 Aug 31;5(6):1126-1140. doi: 10.1016/j.adro.2020.07.009. eCollection 2020 Nov-Dec.

ABSTRACT

PURPOSE: There is increasing use of radical prostatectomy to treat patients with high-risk prostate cancer. This has contributed toward a pathologic stage migration, and a greater number of patients are subsequently being diagnosed with biochemical failure. There is increasing use of advanced imaging techniques in the setting of biochemical failure, including positron emission tomography-computed tomography (PET-CT).

METHODS AND MATERIALS: This critical literature review highlights the evidence for PET-CT in postprostatectomy biochemical failure and identifies sites of pelvic lymph node relapse in the setting of biochemical failure and the potential implications that the locations of these relapses may have for salvage therapies. Potential future directions are then considered.

RESULTS: The optimal PET-CT tracer remains uncertain but there is increasing use of prostate-specific membrane antigen PET-CT for investigating sites of nodal metastasis at low prostate-specific antigen levels, and this is leading to a blurring of the biochemical and radiologic recurrence phases. The optimal therapeutic approach remains undefined, with current trials investigating postoperative radiation therapy to the whole pelvis in addition to the prostatic fossa, the use of PET-CT in the setting of biochemical recurrence to guide delivery of salvage radiation therapy, and, for patients with node-only relapsed prostate cancer, the addition of whole pelvis radiation therapy to metastasis-directed therapies such as stereotactic ablative radiotherapy.

CONCLUSIONS: The most appropriate target volume for salvage radiation therapy remains uncertain, and the findings of studies using PET-CT to map nodal recurrences suggest that there could be a role for extending whole pelvis radiation therapy volumes to increase coverage of superior nodal regions. The emerging fields of radiomics and radiogenomics could provide important prognostic information and aid decision making for patients with relapsed prostate cancer.

PMID:33305073 | PMC:PMC7718540 | DOI:10.1016/j.adro.2020.07.009

Excerpt from:
Patterns of Lymph Node Failure in Patients With Recurrent Prostate Cancer Postradical Prostatectomy and Implications for Salvage Therapies - DocWire...

Earlier this year Douglas J. Kennett, a UC Santa Barbara professor of anthropology, demonstrated that maize, or corn, became a staple crop in the Americas 4,700 years ago. It turns out he was just beginning to tell the story of the worlds biggest grain crop.

In a new paper in the Proceedings of the National Academy of Sciences, Kennett and his co-authors report that by analyzing the genomes of ancient maize they are able to fill in some of the gaps in the 9,000-year-old history of corn, which was first partially domesticated in southwestern Mexico and spread through Central and South America fairly rapidly.

The researchers sequenced the whole genomes of three roughly 2,000-year-old cobs from El Gigante rock shelter in Honduras. Analysis of the genomes yielded a surprise: the millennia-old varieties of Central American maize were more related to ancient and modern corn varieties that were improved in South America, uncovering flows of grains between the regions.

I was most surprised that improved maize varieties developed by Indigenous South Americans were reintroduced northward into Central America, co-lead author Kennett said. We could only know this through whole genome sequencing.

The genetic sleuthing revealed that the arrival of corn from South America may have played a role in the development of more productive varieties and greater consumption in Central America starting about 4,700 years ago.

We show that humans were carrying maize from South America back towards the domestication center in Mexico, said Logan Kistler, curator of archaeogenomics and archaeobotany at the Smithsonians National Museum of Natural History and co-lead author. This would have provided an infusion of genetic diversity that may have added resilience or increased productivity. It also underscores that the process of domestication and crop improvement doesnt just travel in a straight line.

First partially domesticated from teosinte, a wild grass, maize has only reluctantly given up the secrets of its long development. Genetic research, Kennett said, has been challenging because a scarcity of suitable cobs in an environment not kind to organic material. Researchers, however, caught a break in Honduras.

Well-preserved maize is extremely rare in the Americas, but the El Gigante rock shelter has over 10,000 specimens to work with, he said. Most of these fragmentary remains date later than 2,500 years ago, and locating earlier material in the assemblage was challenging and required directly radiocarbon dating large numbers of maize cobs.

Using this approach, Kennett continued, we did identify about 20 early cobs dating to between 4,300-4,000 years ago and we attempted to extract ancient DNA from all of these along with a set of cobs dating to between 2,300 and 1,900 years old. Using the best available techniques we were able to extract working genomes from only three cobs and all of these dated to between 2,300 and 1,900 years ago. This is the frustrating reality of ancient DNA work.

While difficult, the research on maize has entered into a new era of discovery, Kennett said, because whole genome sequencing is revolutionizing our understanding of the past.

We can now know much more about the biochemical processes involved in the domestication process and the sequence of domestication alleles that became fixed during the domestication syndrome, he said. It is also allowing us to track the spread of maize in much greater detail and how these changes altered the path of human history.

Looking ahead, Kennett said that while researchers now know that improved varieties of maize spread from South America into parts of Central America, they dont know when, precisely, it happened. Based on cob morphology, however, theyve hypothesized it occurred by 4,300 years ago.

Testing this hypothesis will require recovering earlier samples with well-preserved genetic material, he said. We also dont know how far north these new varieties spread. This will require whole genome work on cobs of equivalent age farther north (e.g., Mexico). We also dont know if people migrated north carry these newly improved varieties or if seeds simply passed through preexisting exchange networks. This will require working collaboratively with Indigenous populations in Central America to sequence ancient genomes to determine if the appearance of new varieties parallels the appearance of new populations.

Working on the project from UCSB are Amber VanDerwarker, a professor of anthropology, and Richard George, a postdoctoral scholar in the anthropology department. Also on the project are Alejandra Domic, Kenneth Hirth and Thomas Harper from Penn State University, Heather Thakar from Texas A&M University, Robin Allaby from the University of Warwick, and Andres Bergstrm from the Francis Crick Institute.

Read more here:
Kernels of History | The UCSB Current - The UCSB Current

DUBLIN--(BUSINESS WIRE)--The "Gene Therapy Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Global Gene Therapy Market is expected to witness a 28.32% of CAGR during the forecast period (2020 to 2025). Certain factors that are driving the market growth include rising investments in the R&D, technological advancements, and growing prevalence of target diseases.

Gene therapy is no longer considered a futuristic dream and instead, it has become a treatment for the present. Gene therapies are gaining momentum as promising primary successes in clinical studies to accumulate and examples of regulatory approval for licensing rise in number. Somatic cells can now be treated with gene fragments or gene replacements to express required proteins. While gene therapy was originally targeted for the inherited disease, it is now capable of treating a variety of acquired problems including cancer and HIV. Initially delivered through viruses, now there are safer direct or biochemical vectors, while in the future nano-particles might deliver the drug of choice directly to the nucleus of affected cells.

Companies Mentioned

Key Market Trends

Cancer is Expected to Hold Significant Market Share in the Indication Segment

The ever-rising prevalence of cancer all across the globe is majorly driving the growth of this segment. Getting genes into cancer cells has been one of the most difficult aspects of present-day gene therapy. Researchers have been working on finding new as well as better ways of doing this. Usually, the gene is taken into the cancer cell by a carrier known as a vector. The most common types of a carrier that are used in gene therapy are viruses owing to the fact that they can enter cells and eventually deliver genetic material. The viruses are generally changed so that they cannot result in any serious disease. However, they may still cause mild, flu-like symptoms. Some viruses have been modified in the laboratory so that they can target cancer cells only and not the healthy cells. Therefore, they only carry the gene into cancer cells.

North America Dominates the Market and Expected to do Same in the Forecasted Period

For gene therapy, in the United States, the DHHS (Department of Health and Human Services) has been appointed to oversee the clinical trials. Two other organizations within DHHS, the OHRP (Office for Human Research Protections) and the U.S. FDA (Food and Drug Administration), have a specific authority that is described in the CFR (Code of Federal Regulations). All investigators must obey these regulations while conducting clinical gene therapy trials. The increasing approval of various gene therapies by the afore-mentioned organizations is driving the market growth in the region. For instance, in May 2019, AveXis, a Novartis company, announced that the US FDA had approved Zolgensma (onasemnogene abeparvovec-xioi) for treating pediatric patients of less than 2 years of age having spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

Key Topics Covered:

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Investments in the R&D

4.2.2 Technological Advancements

4.2.3 Growing Prevalence of Target Diseases

4.3 Market Restraints

4.3.1 Lack of Standard Regulations

4.3.2 High Price of Products

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION

5.1 By Indication

5.1.1 Cancer

5.1.2 Metabolic Disorders

5.1.3 Eye Disorders

5.1.4 Spinal Muscular Atrophy

5.1.5 Other Indications

5.2 By Technology

5.2.1 Adeno Virus Vector

5.2.2 Adeno-associated Virus Vector

5.2.3 Lentiviral Vector

5.2.4 Retroviral Vector

5.2.5 Herpes Virus Vector

5.2.6 Others

5.3 Geography

5.3.1 North America

5.3.1.1 United States

5.3.1.2 Canada

5.3.1.3 Mexico

5.3.2 Europe

5.3.2.1 Germany

5.3.2.2 United Kingdom

5.3.2.3 France

5.3.2.4 Italy

5.3.2.5 Spain

5.3.2.6 Rest of Europe

5.3.3 Asia Pacific

5.3.3.1 China

5.3.3.2 Japan

5.3.3.3 India

5.3.3.4 Australia

5.3.3.5 South Korea

5.3.3.6 Rest of Asia-Pacific

5.3.4 Middle East and Africa

5.3.4.1 GCC

5.3.4.2 South Africa

5.3.4.3 Rest of Middle East and Africa

5.3.5 South America

5.3.5.1 Brazil

5.3.5.2 Argentina

5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/4vbyuh

See more here:
Worldwide Gene Therapy Industry to 2025 - Cancer is Expected to Hold Significant Market Share in the Indication Segment - ResearchAndMarkets.com -...